ArticleChemMedChem2026
Synthesis of 2-Aryl(alkyl)benzimidazole Hydroxamic Acids as HDAC Inhibitors with Anti-Angiogenesis Properties.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study synthesized a series of C2 and N1-substituted benzimidazole hydroxamic acid (6-19) as HDAC inhibitors. Among them, most of 2-aryl(alkyl)benzimidazole hydroxamic acids (11-16) exhibited HDAC6 activity and slight HDAC1 (or HDAC2) activity. In addition, they also showed anti-angiogenic activity and inhibited the growth of tested cancer cells. For instance, compound 13 has a GI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.